A case of unexpected peripherally inserted central catheter removal from a colorectal cancer patient with cetuximab-induced skin toxicity and contact dermatitis at the peripherally inserted central catheter insertion site: Should we recommend the patient to choose subcutaneous port preferentially?

Abstract

Introduction:

Obtaining central venous access is one of the most commonly performed procedures in cancer patients. However, there are very limited data to guide clinicians when selecting a device for metastatic colorectal cancer patients who received cetuximab.

Case description:

A 54-year-old male patient with metastatic colorectal cancer treated with cetuximab plus FOLFIRI used peripherally inserted central catheter as intravenous pathway. After eight cycles, the patient suffered cetuximab-induced grade 2 skin toxicity and grade 3 contact dermatitis at the peripherally inserted central catheter insertion site. Finally, he removed the peripherally inserted central catheter and accepted subcutaneous port instead for 2 years without implantation cutaneous complication.

Conclusions:

We suggest that metastatic colorectal cancer patients treated with cetuximab should be recommended to choose subcutaneous port preferentially to avoid potential risk of unexpected peripherally inserted central catheter removal due to cetuximab-induced skin toxicity or contact dermatitis. Further clinical practices and researches are needed for more profound evidences for better practical suggestions.

Keywords

Peripherally inserted central catheter subcutaneous port cetuximab-induced skin toxicity contact dermatitis unexpected removal

Get full access to this article

View all access options for this article.

References

Shaw

Shah

Kapoor

, et al. ACR appropriateness criteria® radiologic management of central venous access. J Am Coll Radiol 2017; 14(11S): S506–S529.

Gonda

Principles of subcutaneous port placement. Tech Vasc Interv Radiol 2011; 14(4): 198–203.

Lacouture

Maitland

Segaert

, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 2010; 18(4): 509–522.

Kutzscher

Management of irritant contact dermatitis and peripherally inserted central catheters. Clin J Oncol Nurs 2012; 16(2): E48–E55.

Rubovszky

Budai

Ganofszky

, et al. Predictive value of early skin rash in cetuximab-based therapy of advanced biliary tract cancer. Pathol Oncol Res 2018; 24(2): 237–244.

Lacouture

Mitchell

Piperdi

, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28(8): 1351–1357.

Kobayashi

Komatsu

Yuki

, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: hGCSG1001 study; J-STEPP. Future Oncol 2015; 11(4): 617–627.

Kutzscher

Management of irritant contact dermatitis and peripherally inserted central catheters. Clin J Oncol Nurs 2012; 16(2): E48–E55.

Lacouture

ME.

Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6(10): 803–812.

10.

Robert

Soria

Spatz

, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6(7): 491–500.

11.

Holcmann

Sibilia

Mechanisms underlying skin disorders induced by EGFR inhibitors. Mol Cell Oncol 2015; 2(4): e1004969.